# A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients

> **NCT04847583** · PHASE2 · TERMINATED · sponsor: **Qurient Co., Ltd.** · enrollment: 1 (actual)

## Conditions studied

- COVID-19 Virus Infection

## Interventions

- **DRUG:** Telacebec
- **DRUG:** COVID-19 Standard of care

## Key facts

- **NCT ID:** NCT04847583
- **Lead sponsor:** Qurient Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-29
- **Primary completion:** 2022-02-11
- **Final completion:** 2022-02-11
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Sponsor's Decision
- **Last updated:** 2022-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04847583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04847583, "A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04847583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*